# Safety and Efficacy of Azzalure/Dysport, Restylane/Emervel Filler and Restylane Skinbooster Treatment

> **NCT02297516** · PHASE4 · COMPLETED · sponsor: **Galderma R&D** · enrollment: 65 (actual)

## Conditions studied

- Aesthetics

## Interventions

- **DRUG:** Azzalure or Dysport
- **DEVICE:** Restylane or Emervel filler
- **DEVICE:** Restylane Skinbooster

## Key facts

- **NCT ID:** NCT02297516
- **Lead sponsor:** Galderma R&D
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-11
- **Primary completion:** 2017-03
- **Final completion:** 2017-03
- **Target enrollment:** 65 (ACTUAL)
- **Last updated:** 2022-10-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02297516

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02297516, "Safety and Efficacy of Azzalure/Dysport, Restylane/Emervel Filler and Restylane Skinbooster Treatment". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02297516. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*